Guerbet has announced the first production batch has been manufactured and released for Elucirem (gadopiclenol) injection following US Food and Drug Administration (FDA) approval in September 2022, after priority review. The highly stable macrocyclic gadolinium-based contrast agent (GBCA) has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged two years and older.
Elucirem injection is used to detect and visualise lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
GBCAs improve the contrast between lesions and surrounding tissues by accelerating the relaxation of protons thanks to interaction with gadolinium atoms. Gadopiclenol, the active drug substance of Elucirem, has been designed to enable twice as much interaction, resulting in the highest relaxivity among all non-specific GBCAs. This allows use at half the conventional gadolinium dose to reveal high-quality images.
